FREMONT,
Calif., Nov. 21, 2024 /PRNewswire/ -- ImmunityBio,
Inc. (NASDAQ: IBRX), a vertically integrated biotechnology company,
and nCartes, Inc., a transformational cloud software platform
provider, announced a collaboration agreement aimed at automating
and streamlining the data fulfillment process for clinical trials.
The goal of the collaboration is to make this essential process
easier, faster, and less expensive for ImmunityBio's trial
investigators.
The vast majority of clinical trials today gather data manually
at clinical research sites. The data is then entered by hand into
Electronic Data Capture (EDC) systems used by clinical trial
sponsors. This process is time-consuming, costly, and creates the
potential for errors that can further delay trial results. This new
collaboration will instead rely on using digital information
available in source electronic medical record (EMR) systems to
directly populate EDC systems.
"ImmunityBio's innovations in immunotherapies for cancer and
infectious diseases depend on getting timely and accurate data from
our many ongoing clinical trials," said Richard Adcock, President and CEO of
ImmunityBio. "The EMR-to-EDC capability nCartes provides will
transform this process, reducing delays and enabling us to
potentially bring important therapies to market faster."
Automating the process also will help to reduce data entry
mistakes and thereby improves data quality, which also materially
reduces the cost and elapsed time required for source data
verification.
"ImmunityBio is doing incredible work with its novel immune
system-based therapeutics and vaccines, and has an aggressive
clinical trial program," said John S.
McIlwain, CEO of nCartes. "The nCartes team is honored to
have this opportunity to work alongside the ImmunityBio team and
their research sites to potentially materially improve the crucial
data collection aspect of those trials."
About nCartes
nCartes (https://ncartes.ncoup.com) is a transformational cloud
software platform provider. The nCartes platform enables clinical
research sponsors and research sites to harness electronic health
systems (EHRs) to automate data capture for clinical trials,
patient registries, cell manufacturing and more.
Contact: info@nCoup.com
LinkedIn: www.linkedin.com/company/ncartes-inc
About ImmunityBio
ImmunityBio is a vertically-integrated biotechnology company
developing next-generation therapies and vaccines that bolster the
natural immune system to defeat cancers and infectious diseases.
The company's range of immunotherapy and cell therapy platforms,
alone and together, act to drive and sustain an immune response
with the goal of creating durable and safe protection against
disease. Designated an FDA Breakthrough Therapy,
ANKTIVA® is the first FDA-approved immunotherapy
for non-muscle invasive bladder cancer CIS that activates natural
killer cells, T cells, and memory T cells for a long-duration
response. The company is applying its science and platforms to
treating cancers, including the development of potential cancer
vaccines, as well as developing immunotherapies and cell therapies
that we believe sharply reduce or eliminate the need for standard
high-dose chemotherapy. These platforms and their associated
product candidates are designed to be more effective, accessible,
and easily administered than current standards of care in oncology
and infectious diseases. For more information,
visit www.immunitybio.com and connect with us on X
(Twitter), Facebook, LinkedIn, and Instagram.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/immunitybio-and-ncartes-enter-collaboration-agreement-on-clinical-trial-data-fulfillment-302312171.html
SOURCE nCoup, Inc.